Replies to post #98 on Fate Therapeutics Inc (FATE)

[jondoeuk]

No, but NKTX (working with CRSP [1]) will combine CAR-T plus CAR-NK [2]. Each will be edited to overcome the immunosuppressive TME [3], possibly be edited to reduce rejection (they use healthy donors) and each likely target two different antigens.

Refs:
1 https://www.globenewswire.com/news-release/2021/05/06/2224961/0/en/CRISPR-Therapeutics-and-Nkarta-Announce-Global-Collaboration-to-Develop-Gene-Edited-Cell-Therapies-for-Cancer.html
2 https://www.nkartatx.com/file.cfm/75/docs/Nkarta_AACR_2020_NK_plus_T_4235_9.pdf
3 https://www.nkartatx.com/file.cfm/75/docs/Nkarta_AACR_2020_gene_editing_891_20.pdf